Skip to main content
U.S. flag

An official website of the United States government

Milestone 9.Q

AD Related Dementias – Specific

Develop FTD biomarkers for diagnosis, prediction, and disease monitoring.


Success Criteria

  • Develop, test, and pathologically confirm novel blood/CSF biomarkers or PET ligands for FTLD-tau, -TDP or -FUS during life, including in populations that experience health disparities.
  • Develop, test and validate sensitive, systems-level biomarkers using wearable technologies that monitor FTD progression, including in populations that experience health disparities.

Summary of Key Accomplishments

A public-private biomarkers consortium led by the Foundation for NIH (FNIH) is evaluating neurofilament light chain protein as a biomarker for neurodegeneration in familial forms of FTD. Additionally, an NIH-led proteinopathy consortium has defined the atomic structure of various forms of proteins like Tau that are aggregated in FTD and unveiling promising targets for PET imaging development. In addition, relatively simple blood tests now have the ability to distinguish FTD from other dementias like Alzheimer's, which will be critical for future targeted clinical trials and has the promise of being a relatively inexpensive test that could be more readily applied to underserved populations. Finally, supplemental studies to the large ALLFTD cohort include the use of mobile apps as well as in-home, non-invasive measurements and trackers that have the promise of monitoring the progression of FTD in a highly sensitive manner and directly in an individual's home rather than needing to travel to a clinical research site.

This information is current as of July 2022.


Research Implementation Area
AD Related Dementias - Specific
Timeline
2016–2023
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

nia.nih.gov

An official website of the National Institutes of Health